News
ESLAW
0.1000
0.00%
0.0000
Weekly Report: what happened at ESLA last week (0406-0410)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/10 21:13
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 04/07 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 04/06 17:05
Weekly Report: what happened at ESLA last week (0330-0403)?
Weekly Report · 04/06 10:11
Weekly Report: what happened at ESLA last week (0323-0327)?
Weekly Report · 03/30 10:11
Zacks Small-Cap Research initiates coverage of Estrella Immunopharma with $12/share valuation
Reuters · 03/23 12:03
Weekly Report: what happened at ESLA last week (0316-0320)?
Weekly Report · 03/23 10:08
Estrella Immunopharma FY 2025 net loss widened 48.86% to USD 13.1 million
Reuters · 03/18 10:03
Weekly Report: what happened at ESLA last week (0309-0313)?
Weekly Report · 03/16 10:08
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/10 21:06
Weekly Report: what happened at ESLA last week (0302-0306)?
Weekly Report · 03/09 10:08
Weekly Report: what happened at ESLA last week (0223-0227)?
Weekly Report · 03/02 10:07
Weekly Report: what happened at ESLA last week (0216-0220)?
Weekly Report · 02/23 10:07
Weekly Report: what happened at ESLA last week (0209-0213)?
Weekly Report · 02/16 10:07
Estrella Immunopharma Is Maintained at Buy by D. Boral Capital
Dow Jones · 02/09 12:40
Estrella Immunopharma Price Target Maintained With a $8.00/Share by D. Boral Capital
Dow Jones · 02/09 12:40
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target
Benzinga · 02/09 12:31
Estrella Immunopharma presents updated data on EB103
TipRanks · 02/09 12:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 02/09 12:05
More
Webull provides a variety of real-time ESLAW stock news. You can receive the latest news about Estrella Immunopharma through multiple platforms. This information may help you make smarter investment decisions.
About ESLAW
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.